Drug pricing
Featured Topics
Lead story
Other featured articles
-
Leveraging Precision Medicine to Meet Patient Needs
Precision medicine promises to reduce adverse side effects and time-consuming trial and error processes, but many patients do not know what it is and providers struggle to leverage it effectively.
Posted in -
Cost- Effectiveness of Total State Coverage for Hepatitis C Medications
A Medicaid-Medicare partnership could cover lifesaving hepatitis C medications — and still save $1 to $1.1 billion over 25 years.
Posted in -
Impacts of First-in-Class Drug Approvals on Future in-Class Innovation
Some claim that FDA approval of drugs with uncertain efficacy today will slow future innovation. In fact, the relationship is much more complex.
Posted in -
Association of Drug Rebates and Competition With Out-of-Pocket Coinsurance in Medicare Part D, 2014 to 2018
Research from Schaeffer Center experts Darius Lakdawalla and Meng Li in JAMA Network Open finds U.S. insurers could use drug manufacturer rebates to lower retail pharmacy prices and reduce patient out-of-pocket burden by 38% on average, or 70% in the most competitive drug classes.
Posted in
About this section
High pharmaceutical prices may garner headlines, but innovation must be appropriately incentivized to help solve healthcare’s intractable challenges. The Schaeffer Center connects industry, the academy and government to support the scientific and technological creativity that saves and improves lives — and spurs economic growth.
Our Experts On Drug pricing
Our Work In Drug pricing
-
Spending On Targeted Therapies Reduced Mortality In Patients With Advanced-Stage Breast Cancer
A new Schaeffer Center study analyzes the link between targeted therapies and outcomes among Medicare patients newly diagnosed with breast cancer, finding targeted therapies used in advanced-stage cancers improved mortality, whereas patients with early-stage cancers had little improvement in mortality from targeted drugs.
Categorized in -
Don’t Make Surgery Another COVID Casualty
Investing in minimally invasive tools can free up valuable beds when pandemic surges threaten to overwhelm hospitals, argues Van Nuys and Lakdawalla in MedPage Today.
Categorized in -
Insurer Formularies Complicate the Adoption of Biosimilar Cancer Therapies
A new blog post coauthored by Schaeffer Center experts in Health Affairs finds that insurer preferences for biologic and biosimilar drugs adds cost and complicates the work of hospital pharmacists and physicians.
Categorized in -
Minimally Invasive Surgeries Offer Strategies for Hospitals to Create Surge Capacity
While COVID-19 hospitalizations are down, a new Schaeffer Center white paper highlights the importance of investing in minimally invasive technologies that will allow hospitals to prepare for future surges.
Categorized in -
Reassessing the Value of Minimally Invasive Technologies in the Era of COVID-19
This Schaeffer Center white paper highlights the importance of investing in minimally invasive technologies that will allow hospitals to prepare for future surges.
Categorized in -
Schaeffer Solutions: Health Policy Recommendations for the Biden Administration and 117th U.S. Congress
The USC-Brookings Schaeffer Initiative for Health Policy has developed practical recommendations and analysis in a number of critical policy areas.
Categorized in